Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405531 | 1.00 | MAPT (0.73) | MAPTTDP1GAAALDH1A1MEN1 | |
| SCHEMBL27713896 | 0.86 | MAPT (0.76) | MAPTTDP1ALDH1A1KDM4ELMNA | |
| SCHEMBL28805223 | 0.86 | MAPT (0.56) | MAPTTDP1GAAALDH1A1MEN1 | |
| 2-Hydroxy-3,4-Dimethoxybenzoic Acid SCHEMBL419244 | 0.85 | MAPT (1.00) | MAPTTDP1ALDH1A1KDM4ELMNA | |
| SCHEMBL3043734 | 0.84 | MAPT (0.61) | MAPTTDP1GAAALDH1A1KDM4E | |
| SCHEMBL1421887 | 0.84 | ALDH1A1 (0.59) | MAPTTDP1GAAALDH1A1MEN1 | |
| SCHEMBL29700534 | 0.84 | MAPT (0.61) | MAPTTDP1GAAALDH1A1KDM4E | |
| SCHEMBL30069060 | 0.84 | ALDH1A1 (0.59) | MAPTTDP1GAAALDH1A1MEN1 | |
| SCHEMBL23121012 | 0.83 | MAPT (0.53) | MAPTTDP1GAAALDH1A1KDM4E | |
| SCHEMBL29996551 | 0.83 | MAPT (0.53) | MAPTTDP1GAAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | claimed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | claimed |
| EP-4549424-A1 | NEW LITHIUM EXTRACTING AGENT AND LIQUID ORGANIC MIXTURE THEREOF, AND METHOD FOR EXTRACTING LITHIUM BY MEANS OF EXTRACTION | Beijing Salt Lake Technology Development Company Limited (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-117603219-A | P-glycoprotein inhibitor and preparation method and application thereof | 浙江大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-117534556-A | Novel lithium extractant, liquid organic mixture thereof and method for extracting lithium by extraction | 北京索特莱克科技发展有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2024027447-A1 | NEW LITHIUM EXTRACTING AGENT AND LIQUID ORGANIC MIXTURE THEREOF, AND METHOD FOR EXTRACTING LITHIUM BY MEANS OF EXTRACTION | 北京索特莱克科技发展有限公司 | 2024-02-08 | — | — | WO | disclosed |
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | disclosed |
| CN-115040497-A | Application of paeonol derivative in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-09-13 | — | — | CN | disclosed |
| CN-110498784-B | Nobiletin derivatives or pharmaceutically acceptable salts thereof, and preparation method and application thereof | 广东克冠达医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | disclosed |
| EP-3831821-A1 | COMPOUND FOR TREATING NERVOUS SYSTEM DISEASES AND USE THEREOF | Shaanxi Micot Technology Limited Company (CN) | 2021-06-09 | — | — | EP | disclosed |
| WO-2002074036-A2 | SUBSTITUTED BENZOPYRANONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-09-26 | — | — | WO | disclosed |
| US-20020058700-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-05-16 | — | — | US | disclosed |
| EP-1133467-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-19 | — | — | EP | disclosed |
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000034228-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | disclosed |
| US-5371220-A | Bicyclo-heterocyclic intermediates for cephalosporin compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-06 | — | — | US | disclosed |
| US-5232918-A | Bactericides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5019570-A | Antibioics | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058700-A1 | Ion channel modulating agents | KCNN4, KCNN1, KCNJ2 | MAPT 3687/4885TDP1 3882/4885GAA 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.